Barinthus Biotherapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Barinthus Biotherapeutics CEO'su Bill Enright, Aug2019 tarihinde atandı, in görev süresi 5.25 yıldır. in toplam yıllık tazminatı $ 1.81M olup, şirket hissesi ve opsiyonları dahil olmak üzere 33.7% maaş ve 66.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.09% ine doğrudan sahiptir ve bu hisseler $ 1.11M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 4.8 yıldır.

Anahtar bilgiler

Bill Enright

İcra Kurulu Başkanı

US$1.8m

Toplam tazminat

CEO maaş yüzdesi	33.7%
CEO görev süresi	5.3yrs
CEO sahipliği	3.1%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%

Nov 19

Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Aug 31

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

Apr 05

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Aug 15

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 13

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Aug 09

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

May 19

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 03

Vaccitech: The Next Big Vaccine Trade

Jun 27

Vaccitech EPS misses by $0.69, beats on revenue

Jun 14

CEO Tazminat Analizi

Bill Enright'un ücretlendirmesi Barinthus Biotherapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$58m
Jun 30 2024	n/a	n/a	-US$64m
Mar 31 2024	n/a	n/a	-US$71m
Dec 31 2023	US$2m	US$610k	-US$73m
Sep 30 2023	n/a	n/a	-US$77m
Jun 30 2023	n/a	n/a	-US$55m
Mar 31 2023	n/a	n/a	-US$15m
Dec 31 2022	US$2m	US$569k	US$5m
Sep 30 2022	n/a	n/a	US$11m
Jun 30 2022	n/a	n/a	-US$1m
Mar 31 2022	n/a	n/a	-US$33m
Dec 31 2021	US$3m	US$474k	-US$51m
Sep 30 2021	n/a	n/a	-US$46m
Jun 30 2021	n/a	n/a	-US$41m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	US$3m	US$350k	-US$18m
Dec 31 2019	US$381k	US$128k	-US$21m

Tazminat ve Piyasa: Bill 'nin toplam tazminatı ($USD 1.81M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 649.07K ).

Tazminat ve Kazançlar: Bill 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Bill Enright (62 yo)

5.3yrs

Görev süresi

US$1,811,611

Tazminat

Mr. William J. Enright, also known as Bill, MBA, is an Independent Director of Bullfrog AI Holdings, Inc. from February 14, 2023. He serves as Chief Executive Officer & Director of Barinthus Biotherapeutic...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
William Enright	CEO & Director	5.3yrs	US$1.81m	3.09% $ 1.1m
Graham Griffiths	Chief Operating Officer	less than a year	US$731.06k	0.26% $ 93.2k
Nadege Pelletier	Chief Scientific Officer	1.8yrs	US$1.71m	0% $ 0
Sarah Gilbert	Co-Founder	no data	US$48.98k	Veri yok
Adrian Hill	Co-Founder & Scientific Advisor	no data	US$61.61k	Veri yok
Gemma Brown	CFO & Company Secretary	2.2yrs	Veri yok	Veri yok
Elizabeth Eagling-Vose	Head of Clinical Operations	no data	Veri yok	Veri yok
Bernie McDonald	Head of IP	no data	Veri yok	Veri yok
Geoffrey Lynn	Senior Vice President of Synthetic Immunotherapies	no data	Veri yok	Veri yok
Leon Hooftman	Chief Medical Officer	less than a year	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

45yo

Ortalama Yaş

Deneyimli Yönetim: BRNS 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
William Enright	CEO & Director	5.3yrs	US$1.81m	3.09% $ 1.1m
Karen Dawes	Independent Non-Executive Director	3.8yrs	US$81.69k	0.0042% $ 1.5k
Anne Phillips	Independent Non-Executive Director	3.8yrs	US$81.06k	0.0075% $ 2.7k
Robin Wright	Independent Chairman of the Board	6.3yrs	US$117.13k	0.12% $ 43.2k
Pierre Armand Morgon	Independent Non-Executive Director	6.8yrs	US$85.42k	0.026% $ 9.4k
Alex Hammacher	Non-Executive Director	4.8yrs	US$71.11k	0.0075% $ 2.7k
Benoit den Eynde	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Mark Tuthill	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Joseph C. Scheeren	Independent Non-Executive Director	3.7yrs	US$79.82k	0.057% $ 20.6k

4.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BRNS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Barinthus Biotherapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective from Beginning of June 2024

Barinthus Biotherapeutics plc, Annual General Meeting, May 10, 2024

Insufficient new directors

Vaccitech plc Announces Retirement of Margaret Marshall as Chief Medical Officer

Vaccitech Appoints Nadège Pelletier as Chief Scientific Officer

Vaccitech plc Promotes Gemma Brown as Chief Financial Officer

Recent updates

Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Barinthus Biotherapeutics plc Plans to Priority on the Development of VTP-300 in Chronic Hepatitis B Virus Infection, or CHB, and VTP-1000 in Celiac Disease

Barthus Biotherapeutics plc Announces Updated Data from Two Clinical Trials in People with Chronic Hepat B

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.48 loss in 1Q 2023)

Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective from Beginning of June 2024

BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

New minor risk - Share price stability

Consensus revenue estimates increase by 29%

Barinthus Biotherapeutics plc, Annual General Meeting, May 10, 2024

New major risk - Revenue size

Full year 2023 earnings released: US$1.91 loss per share (vs US$0.14 profit in FY 2022)

Insufficient new directors

New minor risk - Market cap size

Consensus revenue estimates decrease by 20%, EPS upgraded

Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD

Third quarter 2023 earnings released: US$0.36 loss per share (vs US$0.22 profit in 3Q 2022)

Vaccitech plc(NasdaqGM:VACC) dropped from NASDAQ Composite Index

Price target decreased by 24% to US$9.31

Consensus revenue estimates increase by 26%

Consensus revenue estimates decrease by 53%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Vaccitech plc Announces Retirement of Margaret Marshall as Chief Medical Officer

We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Vaccitech plc Announces Positive Final Data EASL Congress for Phase 1B/2 HBV002 Study in Adults with Chronic Hepatitis B

Vaccitech plc Doses First Patient in Pca001, A Prostate Cancer Phase 1/2 Clinical Trial of Vtp-850

Consensus revenue estimates decrease by 28%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates increase by 12%, EPS downgraded

Price target decreased by 28% to US$14.33

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorates as stock falls 17%

Vaccitech Appoints Nadège Pelletier as Chief Scientific Officer

Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Vaccitech plc Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Vaccitech plc Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients

Vaccitech plc Announces Publication of Research in Preclinical Animal Models Demonstrating the Potential of Vaccitech’s SNAPvax

Vaccitech plc Promotes Gemma Brown as Chief Financial Officer

Vaccitech promotes Gemma Brown to CFO

Consensus revenue estimates increase by 61%

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$19.50

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Vaccitech plc Announces an Update to the Interim Analysis of Safety and Efficacy Data from the HBV002 Study

Arbutus Biopharma Corporation and Vaccitech plc Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

Consensus revenue estimates increase by 51%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vaccitech plc, Annual General Meeting, Jun 15, 2022

Less than half of directors are independent

Consensus forecasts updated

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Vaccitech plc Announces First Patient Dose in Phase I/Iia Trial of Lung Cancer Immunotherapy Vaccine

Vaccitech plc (NasdaqGM:VACC) acquired Avidea Technologies for $40 million.

Third quarter 2021 earnings released: US$0.13 loss per share

Vaccitech: The Next Big Vaccine Trade

Vaccitech EPS misses by $0.69, beats on revenue